Wolfe Research Lifts PT for Johnson & Johnson (JNJ), Keeps Outperform Rating

Group 1 - Johnson & Johnson (NYSE:JNJ) is recognized as one of the 10 Unrivaled Stocks for the next three years, with Wolfe Research raising its price target from $175 to $195 while maintaining an Outperform rating [1] - Wolfe Research's increased confidence in Johnson & Johnson's upcoming talc litigation outcome has led to lower weighted average cost of capital (WACC) assumptions in its discounted cash flow analysis [1] - Despite challenges in the pharmaceutical industry for 2025, including sector-specific tariffs and Most-Favored-Nation prescription drug pricing, Wolfe Research maintains a positive outlook on Johnson & Johnson's growth prospects, particularly from its Innovative Medicine division [2] Group 2 - Johnson & Johnson is an American multinational healthcare company specializing in pharmaceuticals and medical technologies [3] - While Johnson & Johnson is viewed as a potential investment, certain AI stocks are considered to offer greater upside potential and less downside risk [3]